Sarepta Therapeutics (SRPT) Gains on Bullish Article
Get Alerts SRPT Hot Sheet
Join SI Premium – FREE
Sarepta Therapeutics (NASDAQ: SRPT) is gaining pre-open after TheStreet's Adam Feuerstein saying the drug could be approved despite the negative panel.
Feuerstein commented, "Minutes after the advisory panel adjourned on Monday night, Woodcock met with some of the DMD boys and their families. Terri Ellsworth posted a picture of a smiling Woodcock standing next to her son, Billy, on her Facebook page."
Shares of SRPT are up 14% pre-open.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- IBM tumbles on soft Q1 revenue; announces HashiCorp $6.4bn acquisition
- Boeing (BA) Cut To Baa3 From Baa2 By Moody's, Outlook Negative
- US DoJ to Decide by as Soon as Late May Whether Boeing Violated Prosecution Deal - Reuters
Create E-mail Alert Related Categories
FDA, Momentum Movers, Trader TalkRelated Entities
Pre Market Movers, Adam FeuersteinSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!